Eugene Ceppa
Appearances
- DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
Indiana University School of MedicineIndiana University - DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
Indiana UniversityIndiana University School of Medicine - DateMay 6, 2023We present the case of a 67-year-old woman who had two IPMN in the pancreas body (4 and 2 cm) and underwent robotic distal pancreatectomy with spleen preservation…
Presenter
Speakers
- DateMay 19, 2024BACKGROUND: Accurate clinical staging plays a key role in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC)…
Presenter
Speakers
Indiana UniversityIndiana University School of Medicine - DateMay 19, 2024BACKGROUND: Historical pediatric data recommend surgical resection for type I choledochal cysts due to the risk of malignant progression over time up to 30%…
Presenter
Speakers
Indiana University School of MedicineIndiana University - DateMay 19, 2024Laparoscopic subtotal cholecystectomy (STC) is an established approach for difficult cholecystectomy (CCY) and is endorsed by guidelines as a strategy to mitigate risk for complications such as bile duct injury…
Presenter
Speakers
Indiana University School of MedicineIndiana UniversityIndiana University School of Medicine - DateMay 20, 2024Patients with chronic pancreatitis (CP) predominantly involving the pancreatic body/tail benefit from distal pancreatectomy (DP), with most experiencing long-term improvements in symptoms after recovery from surgery…
Presenter
Speakers
Indiana University School of MedicineIndiana University GOBLET CELL ADENOCARCINOMA AND RESPONSE TO TREATMENT - SINGLE CENTER EXPERIENCE OF A RARE MALIGNANCY
DateMay 21, 2024Goblet cell adenocarcinoma is a rare malignancy with an incidence of 1 per 2 million people worldwide…Presenter
Speakers
Indiana UniversityIndiana University School of Medicine- DateMay 21, 2024Splenectomy carries risk of infectious complications. Splenic preservation (SP) avoids these immunologic consequences but is not common surgical practice. When permissible by clinical status and pathology, SP may be acceptable in select patients…
Presenter
Speakers
- DateMay 21, 2024Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed after reaching an advanced stage. High-risk patients with genetic predisposition (ie…